Basel, Switzerland, December 29, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of January 1, 2017, Ursula Eberhardt will take the role of Head of Global Human Resources and join the Extended Management Committee which reports to the Chief Executive Officer. Ms. Eberhardt succeeds Heidi McDaid, who retires as of December 31, 2016. Ms. Eberhardt has served in various positions in Basilea's Corporate Department and Human Resources team since joining Basilea in 2006 and most recently was deputy Head of Global Human Resources.
Ronald Scott, Basilea's Chief Executive Officer, indicated: "Basilea greatly appreciates Ms. McDaid who built Basilea's human resources department and operations from our founding to a level of industry excellence. Basilea's human resources activities will continue to be in good hands under Ms. Eberhardt, who has been our deputy Head of Global Human Resources for the last seven years. We wish Ms. McDaid all the best in her retirement and much success to Ms. Eberhardt in her new position."
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations +41 61 606 1102 [email protected] [email protected] |
This press release can be downloaded from www.basilea.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/d56fddc3-2502-430d-adbc-9a2ff077d4bd


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Instagram Outage Disrupts Thousands of U.S. Users
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 



